[Local mitomycin-C therapy of infiltrating bladder cancer].
Adjuvant local chemotherapy for superficial cancer of the urinary bladder (TA-Tis) is meanwhile performed on a nearly standardized level. The indication for infiltrating tumours (T1-T4) however is controversial. The prevention of tumour cell implantation which is promoted by transurethral resections is advantageous. On the other hand a curative effect cannot be expected from local chemotherapy in infiltrating tumours. The long-term results of adjuvant local chemotherapy in 86 patients with infiltrating urinary bladder carcinomas are reported, who received mitomycin instillations after transurethral resections.
D000287:Administration, Topical; D003131:Combined Modality Therapy; D003556:Cystitis / Q000139:chemically induced; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009366:Neoplasm Seeding / Q000517:prevention & control; D009367:Neoplasm Staging; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
D008937:Mitomycins; D016685:Mitomycin
Lokale Mitomycin-C-Therapie des infiltrierenden Harnblasenkarzinoms.